Erasca (ERAS) Stock Forecast, Price Target & Predictions
ERAS Stock Forecast
Erasca stock forecast is as follows: an average price target of $7.00 (represents a 135.69% upside from ERAS’s last price of $2.97) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ERAS Price Target
The average price target for Erasca (ERAS) is $7.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 135.69% upside from ERAS's last price of $2.97.
ERAS Analyst Ratings
According to 3 Wall Street analysts, Erasca's rating consensus is 'Buy'. The analyst rating breakdown for ERAS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Erasca Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 01, 2024 | Chris Shibutani | Goldman Sachs | $7.00 | $2.21 | 216.74% | 135.69% |
The latest Erasca stock forecast, released on Apr 01, 2024 by Chris Shibutani from Goldman Sachs, set a price target of $7.00, which represents a 216.74% increase from the stock price at the time of the forecast ($2.21), and a 135.69% increase from ERAS last price ($2.97).
Erasca Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.97 | $2.97 | $2.97 |
| Upside/Downside | -100.00% | -100.00% | 135.69% |
In the current month, the average price target of Erasca stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Erasca's last price of $2.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 01, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 03, 2023 | Morgan Stanley | - | Overweight | Upgrade |
Erasca's last stock rating was published by H.C. Wainwright on Aug 13, 2024. The company gave ERAS a "Buy" rating, the same as its previous rate.
Erasca Financial Forecast
Erasca Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Erasca's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ERAS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Erasca EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict ERAS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Erasca's previous annual EBITDA (undefined) of $NaN.
Erasca Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-65.20M | $-62.85M | $-58.07M | $-55.71M | $-60.39M | $-58.21M | $-53.79M | $-51.59M | $-43.56M | $-43.56M | $-41.38M | $-39.21M | $-35.98M | $-37.72M | $-39.87M |
| High Forecast | $-65.20M | $-62.85M | $-58.07M | $-55.71M | $-60.39M | $-58.21M | $-53.79M | $-51.59M | $-43.56M | $-43.56M | $-41.38M | $-39.21M | $-35.98M | $-33.53M | $-39.87M |
| Low Forecast | $-65.20M | $-62.85M | $-58.07M | $-55.71M | $-60.39M | $-58.21M | $-53.79M | $-51.59M | $-43.56M | $-43.56M | $-41.38M | $-39.21M | $-35.98M | $-44.01M | $-39.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Erasca's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ERAS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Erasca SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Erasca's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ERAS last annual SG&A of $NaN (undefined).
Erasca EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.20 | $-0.20 | $-0.19 | $-0.18 | $-0.17 | $-0.17 | $-0.18 |
| High Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.20 | $-0.20 | $-0.19 | $-0.18 | $-0.17 | $-0.15 | $-0.18 |
| Low Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.20 | $-0.20 | $-0.19 | $-0.18 | $-0.17 | $-0.20 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Erasca's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ERAS previous annual EPS of $NaN (undefined).
Erasca Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.24 | $21.86 | 574.69% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| OLMA | Olema Pharmaceuticals | $12.70 | $27.00 | 112.60% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ERAS Forecast FAQ
Is Erasca a good buy?
Yes, according to 3 Wall Street analysts, Erasca (ERAS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ERAS's total ratings.
What is ERAS's price target?
Erasca (ERAS) average price target is $7 with a range of $7 to $7, implying a 135.69% from its last price of $2.97. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Erasca stock go up soon?
According to Wall Street analysts' prediction for ERAS stock, the company can go up by 135.69% (from the last price of $2.97 to the average price target of $7), up by 135.69% based on the highest stock price target, and up by 135.69% based on the lowest stock price target.
Can Erasca stock reach $4?
ERAS's average twelve months analyst stock price target of $7 supports the claim that Erasca can reach $4 in the near future.
What are Erasca's analysts' financial forecasts?
Erasca's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-224M (high $-224M, low $-224M), average SG&A $0 (high $0, low $0), and average EPS is $-1.028 (high $-1.028, low $-1.028). ERAS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-242M (high $-242M, low $-242M), average SG&A $0 (high $0, low $0), and average EPS is $-1.11 (high $-1.11, low $-1.11).